Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy

Anna Elisabetta Brunetti, Sabina Delcuratolo, Vito Lorusso, Loredana Palermo, Angelo Di Giorgio, Salvatore Pisconti, Nicola Silvestris

Research output: Contribution to journalArticle

Abstract

Background: Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. Case Report: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. Results: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.

Original languageEnglish
Pages (from-to)3683-3688
Number of pages6
JournalAnticancer Research
Volume34
Issue number7
Publication statusPublished - Jul 1 2014

Keywords

  • Chemotherapy
  • Desmoplastic small round cell tumour
  • Multimodal therapy
  • Trabectedin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy'. Together they form a unique fingerprint.

  • Cite this